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Visual and quantitative evaluation of
[18F]FES and [18F]FDHT PET in patients with
metastatic breast cancer: an interobserver
variability study
Lemonitsa H. Mammatas1, Clasina M. Venema2, Carolina P. Schröder2, Henrica C. W. de Vet3, Michel van Kruchten2,
Andor W. J. M. Glaudemans4, Maqsood M. Yaqub5, Henk M. W. Verheul1, Epie Boven1, Bert van der Vegt6,
Erik F. J. de Vries2, Elisabeth G. E. de Vries2, Otto S. Hoekstra5, Geke A. P. Hospers2 and
C. Willemien Menke-van der Houven van Oordt1*
Abstract
Purpose: Correct identification of tumour receptor status is important for treatment decisions in breast cancer.
[18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR)
status of individual lesions within a patient. Despite standardised analysis techniques, interobserver variability can
significantly affect the interpretation of PET results and thus clinical applicability. The purpose of this study was to
determine visual and quantitative interobserver variability of [18F]FES PET and [18F]FDHT PET interpretation in
patients with metastatic breast cancer.
Methods: In this prospective, two-centre study, patients with ER-positive metastatic breast cancer underwent both
[18F]FES and [18F]FDHT PET/CT. In total, 120 lesions were identified in 10 patients with either conventional imaging
(bone scan or lesions > 1 cm on high-resolution CT, n = 69) or only with [18F]FES and [18F]FDHT PET (n = 51). All
lesions were scored visually and quantitatively by two independent observers. A visually PET-positive lesion was
defined as uptake above background. For quantification, we used standardised uptake values (SUV): SUVmax, SUVpeak
and SUVmean.
Results: Visual analysis showed an absolute positive and negative interobserver agreement for [18F]FES PET of 84%
and 83%, respectively (kappa = 0.67, 95% CI 0.48–0.87), and 49% and 74% for [18F]FDHT PET, respectively (kappa =
0.23, 95% CI − 0.04–0.49). Intraclass correlation coefficients (ICC) for quantification of SUVmax, SUVpeak and SUVmean
were 0.98 (95% CI 0.96–0.98), 0.97 (95% CI 0.96–0.98) and 0.89 (95% CI 0.83–0.92) for [18F]FES, and 0.78 (95% CI 0.66–
0.85), 0.76 (95% CI 0.63–0.84) and 0.75 (95% CI 0.62–0.84) for [18F]FDHT, respectively.
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Conclusion: Visual and quantitative evaluation of [18F]FES PET showed high interobserver agreement. These results
support the use of [18F]FES PET in clinical practice. In contrast, visual agreement for [18F]FDHT PET was relatively low
due to low tumour-background ratios, but quantitative agreement was good. This underscores the relevance of
quantitative analysis of [18F]FDHT PET in breast cancer.
Trial registration: ClinicalTrials.gov, NCT01988324. Registered 20 November 2013, https://clinicaltrials.gov/ct2/show/
NCT01988324?term=FDHT+PET&draw=1&rank=2.
Keywords: FES PET, FDHT PET, Breast cancer, Oestrogen receptor, Androgen receptor, Interobserver variability
Introduction
Breast cancer is the most common malignancy in
women in the Western world. The majority of breast tu-
mours express the oestrogen receptor (ER), which is the
main indicator of potential response to anti-oestrogen
therapies [1, 2]. Therefore, it is mandatory to determine
ER expression in breast cancer. Recently, the androgen
receptor (AR) emerged as a possible target for breast
cancer therapy. The AR is present in 70–80% of patients
with breast cancer, and AR antagonists are under inves-
tigation in clinical trials [3–6].
A tumour biopsy is the gold standard to determine re-
ceptor expression. However, this is an invasive procedure,
is not always feasible in case of inaccessible tumour sites,
and is subject to sampling errors [7]. The 16α-[18F]fluoro-
17β-oestradiol ([18F]FES) and 16β-[18F]fluoro-5α-dihydro-
testosterone ([18F]FDHT) PET/CT have been developed
to non-invasively visualise, respectively, the ER and AR
status in the tumour lesions within a patient. Previously, it
has been shown that [18F]FES and [18F]FDHT uptake cor-
relate well with ER and AR expression levels in represen-
tative breast cancer biopsies [8–10]. As a diagnostic tool,
[18F]FES PET leads to better diagnostic understanding in
88% and to a change of therapy in 48% of the patients pre-
senting with a clinical dilemma [11]. To predict treatment
effects, [18F]FES PET can be used to assess residual ER
availability during treatment with, e.g. fulvestrant, a select-
ive ER downregulator. Inadequate reduction of the
[18F]FES PET signal (< 75%) by fulvestrant treatment was
associated with early progression [12]. Similarly, in pa-
tients with prostate cancer, [18F]FDHT PET was used to
determine the optimal dose of the AR blocker enzaluta-
mide in a phase 1 trial [13]. Lastly, patients with ER-
positive breast cancer and high [18F]FDG uptake showed a
worse progression free survival if [18F]FES uptake was low
in comparison to high [18F]FES uptake (3 versus 8months,
respectively) [14].
For all these potential applications, reliable, observer-
independent identification and quantification of [18F]FES
and [18F]FDHT uptake in tumour lesions is essential for
translation to daily clinical practice. Up till now, there
are no data on the interobserver variability of [18F]FES
and [18F]FDHT PET in breast cancer. Therefore, the
primary objective of this study was to examine interob-
server variability in visual and quantitative assessment of
[18F]FES and [18F]FDHT PET. Secondary objectives in-
cluded the effect of tumour to background ratio (TBR),
tracer accumulation, tumour size and the use of different
SUV parameters (SUVmax, SUVpeak or SUVmean) on in-
terobserver agreement. Also, the added value of quanti-
tative assessment in comparison to visual assessment
was examined, and the number of lesions detected on
[18F]FES and [18F]FDHT was compared with those de-
tected on conventional imaging methods (contrast en-
hanced CT scan and bone scan).
Materials and methods
Patient population
This prospective two-centre interobserver variability
study was part of a study investigating the correl-
ation between [18F]FES and [18F]FDHT uptake and
ER and AR expression in simultaneously biopsied
metastases, of which the results have been published
elsewhere [8]. Patients were recruited from Septem-
ber 2014 to August 2015 at the CCA-VUmc Univer-
sity Medical Center Amsterdam and the University
Medical Center Groningen in the Netherlands.
Eligibility criteria included metastatic breast cancer
and an ER-positive primary tumour, ≥ 1 extrahepatic
tumour lesion, ECOG performance status of ≤ 2 and
a postmenopausal status or use of LHRH-agonists.
Patients were excluded if they had used ER or AR
binding drugs during the 6 weeks before study entry,
because these ligands compete with tracer binding.
All patients had to give written informed consent before
study participation. The study was conducted in compli-
ance with the ethical principles originating in or derived
from the Declaration of Helsinki and in compliance with
all International Conference on Harmonization Good
Clinical Practice guidelines. The local medical ethics com-
mittee approved the study (NCT01988324).
Imaging protocols
[18F]FES and [18F]FDHT were produced as described
previously [15, 16]. On separate days, ≤ 14 days apart,
200MBq (± 10%) of each tracer was injected. After 60
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min (± 5min), a low-dose CT was performed during
tidal breathing for attenuation correction, followed by a
whole-body PET scan (skull vertex to mid-thigh, 2 min
per bed position). PET/CT scans were made using a Phi-
lips Gemini TF-64 PET/CT (Amsterdam) or Siemens 64
slice mCT PET/CT (Groningen). Acquisition and recon-
struction protocols used on both scanners were accord-
ing to the recommendations of the European
Association of Nuclear Medicine (EARL) [17].
In addition, a high-resolution, contrast-enhanced CT
chest-abdomen and bone scan was performed within 6
weeks of the PET scans for comparison.
Image analyses
Contrast enhanced CT scans were examined by experi-
enced radiologists and bone scans by experienced nu-
clear medicine physicians, respectively, masked for the
[18F]FES and [18F]FDHT PET results. Two independent
observers from each centre (LM and CV), trained and
supervised by two experienced nuclear medicine physi-
cians, performed visual and quantitative analyses. The
observers had knowledge of conventional imaging results
(contrast enhanced CT and bone scans).
A visually PET-positive lesion was defined as focal up-
take above local background incompatible with physio-
logical uptake. Liver metastases were excluded from all
analyses in this study because of high physiological
[18F]FES and [18F]FDHT uptake in healthy liver tissue,
making reliable identification of metastases difficult. In
addition, if visual interpretation of uptake in a (potential)
lesion was impossible, e.g. due to overlap with adjacent
organs with high physiological tracer, the readers inde-
pendently reported it as ‘not evaluable’ in the visual rat-
ings, and these were excluded from further analyses. For
each patient, the observers made a list that consisted of
all lesions already detected on conventional imaging,
followed by additional lesions discovered on [18F]FES or
[18F]FDHT PET. An anatomical description of all the le-
sions was reported in order to match the results. In case
a lesion was not reported by one of the two observers, it
was scored as not visible for that observer. All visually
PET-positive lesions were quantified, as well as PET-
negative lesions that were identified on conventional im-
aging (i.e. lesions on bone scintigraphy and/or high reso-
lution CT > 1 cm).
Each observer manually drew volumes of interest
(VOI) on the tumour contours, using PET images for
PET-positive lesions and low-dose CT images for PET-
negative lesions (lesions only seen on bone scan or high-
resolution CT were visually matched on the low-dose
CT). Lesions were separately analysed based on visibility
on either PET or conventional imaging alone to investi-
gate the influence of visibility on imaging techniques on
interobserver agreement.
For every VOI, the standardised uptake values (SUV),
i.e. the tracer uptake within a VOI normalised to the
injected dose and body weight, were calculated using the
software programs accurate (in-house build using IDL,
observer 1) and syngo.via version VB10B, Siemens (ob-
server 2). Both programs yielded identical results on test
images. Three types of SUV were compared in this
study: SUVmax (voxel with highest SUV within the VOI),
SUVpeak (average SUV of a 1 cm
3 sphere containing the
hottest voxels of the VOI) and SUVmean with isocontour
50% of SUVmax (average SUV of all voxels with uptake ≥
50% of SUVmax).
Based on previous studies, an SUVmax [
18F]FES cut-off
≥ 1.5 was used to define ER-positivity (corresponding
with a IHC cut-off of ≥ 1%) and an SUVmax [
18F]FDHT
cut-off ≥ 1.9 for AR positivity (corresponding with a
IHC cut-off of ≥ 10%) [8, 9].
For [18F]FES and [18F]FDHT, the SUVmax tumour-
background ratio (TBR) was defined as the ratio of the
SUVmax of a tumour lesion and the SUVmean of healthy
background tissue. To determine the SUVmean of healthy
background tissue, a VOI was drawn on reference tissue
in the unaffected contralateral site whenever available or
in the unaffected surrounding tissue of the same origin
[18].
Statistical analyses
For visual assessments, agreement was calculated with
absolute and relative measures of interobserver agree-
ment. Absolute agreement is the probability that if one
observer would score a lesion as visible (positive agree-
ment) or not visible (negative agreement) on the PET
scan, the other observer would do the same. It is calcu-
lated by the following formulas: positive agreement = 2
× lesions visible to both observers/(2 × lesions visible to
both observers + lesions only visible to observer 1 + le-
sions only visible to observer 2) and negative agreement
= 2 × lesions not visible to both observers/(2 × lesions
not visible to both observers + lesions only not visible to
observer 1 + lesions only not visible to observer 2) [19].
In order to compare results with previous studies, also
reliability (relative agreement) was calculated according
to Cohen’s kappa, and the results were interpreted as
follows: kappa 0.01–0.20 as slight, 0.21–0.40 as fair,
0.41–0.60 as moderate, 0.61–0.80 as substantial and
0.81–1.00 as almost perfect interobserver agreement
[20]. To account for potential within-person correlation
in visual assessments, a chi-square test was performed to
examine whether the percentage visual agreement dif-
fered per patient.
For quantitative assessments, parameters are presented
as mean ± SD, and reliability was calculated with intra-
class correlation coefficients (ICC) using a two-way ran-
dom effect model with absolute agreement. For the
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interpretation of the ICCs, the following guideline was
used: ≥ 0.90 as excellent, ≥ 0.75 as good, ≥ 0.50 as mod-
erate and < 0.50 as poor [21].
Absolute agreement on quantitative assessments
were analysed with Bland-Altman plots (differences
between observers showed a normal distribution). For
each lesion, it graphically shows the average SUV of
observers 1 and 2 on the x-axes and on the y-axes
the difference between observers for each lesion,
expressed as percentage of the average SUV value.
Percentage differences were used instead of absolute
differences to achieve independence of magnitude of
differences from magnitude of SUV values, and it fa-
cilitates comparisons between the SUV parameters
SUVmax, SUVmean and SUVpeak, which may show large
differences in absolute values.
To investigate the effect of TBRs on interobserver vari-
ability, differences between TBRs of [18F]FES and
[18F]FDHT PETs were tested with Wilcoxon matched
pairs signed rank tests. In addition, correlations between
tracer uptake or tumour size and percentage interob-
server differences were determined using the Spearman
correlation coefficient (r). Finally, linear regression was
performed to find the linear function between SUVmax,
SUVpeak and SUVmean for [
18F]FES and [18F]FDHT PET,
and Cochran’s Q and McNemar tests were used to ana-
lyse differences between visibility and quantitative up-
take above or below cut-off for SUVmax, SUVpeak and
SUVmean. P value < 0.05 was considered significant. Stat-
istical analyses were generated using the SPSS software
(version 22; IBM, SPSS statistics).
Results
Patient characteristics
A total of 120 lesions were identified in 10 patients using
the different imaging modalities (Table 1). Most lesions
were skeletal (66%), followed by lymph node (25%) and
visceral metastases (9%). The median number of lesions
per patient was 9 (range 2–32).
Comparison of lesion detection on different imaging
modalities
Of the 120 lesions in total (Table 1), most were identi-
fied on [18F]FES PET (n = 64 [53%] and n = 69 [58%] by
observer 1 and 2, respectively), followed by high-
resolution CT (n = 54 [45%]), bone scintigraphy (n = 40
[33%]) and [18F]FDHT PET (n = 36 [30%] and n = 37
[31%]). Fifty and 42% of the lesions identified on
[18F]FES PET by observer 1 and 2, respectively, were also
detected on high resolution CT or bone scintigraphy
(Fig. 1). For [18F]FDHT PET, 55% and 49% of the identi-
fied lesions were seen with conventional imaging. Con-
versely, 46 and 42% of the lesions identified on
conventional imaging were visible on [18F]FES PET by,
respectively, observer 1 and 2, and 29% and 26% were
seen on [18F]FDHT PET. In particular, more lymph node
Table 1 Patient characteristics
Characteristic Number (n = 10) %
Age in years, mean (range) 67 (48–79)









Visible lesions: total, median per patient (range) 120, 9 (2–32)
Conventional imaging (CT, bone scan) 69 (54, 40) 58 (45, 33)
Visible on PET alone ([18F]FES or [18F]FDHT PET) 51 (33, 20) 42 (28, 16)
Total visible on [18F]FES PET (observer 1, 2) 64, 69 53, 58
Total visible on [18F]FDHT PET (observer 1, 2) 36, 37 30, 31
Location
Bone (conventional imaging, [18F]FES, [18F]FDHT PET) 79 (55, 45, 37) 66 (80, 54, 64)
Lymph node (conventional imaging, [18F]FES; [18F]FDHT PET) 30 (8, 29, 16) 25 (12, 35, 28)
Viscerala (conventional imaging, [18F]FES, [18F]FDHT PET) 11 (6, 9, 5) 9 (9, 11, 9)
aExcluding liver
Mammatas et al. EJNMMI Research           (2020) 10:40 Page 4 of 12
lesions were detected on [18F]FES PET and [18F]FDHT
PET compared to conventional imaging: 97% and 53%
versus 27% of all detected lymph node lesions,
respectively.
Visual analysis of [18F]FES and [18F]FDHT PET images
Out of 120 lesions, a total of 87 and 74 on [18F]FES and
[18F]FDHT PET, respectively, were analysed for visual
interobserver agreement. The other lesions were ex-
cluded because one or both observers reported these as
‘not evaluable’ due to overlap with adjacent organs with
high physiological tracer uptake.
For lesions visible on conventional imaging, [18F]FES
PET readings (Table 2) had substantial positive and
negative agreement of 84% (95% CI 72–92%) and 83%
(95% CI 70–91%), respectively (kappa = 0.67, 95% CI
0.48–0.87). By including lesions that were only visible
on [18F]FES PET, the positive agreement improved to
88% (95% CI 80–93%) for all lesions scored on
[18F]FES PET (negative agreement remained the
same). [18F]FDHT PET showed lower positive agree-
ment of 49% (95% CI 32–65%) for lesions visible on
conventional imaging, while negative agreement was
74% (95% CI 62–83%) (kappa = 0.23, 95% CI − 0.04–
0.49). Positive agreement for all lesions scored on
[18F]FDHT PET was 58% (95% CI 43–71%). By look-
ing at lesions only visible on PET and not on conven-
tional imaging, the positive agreement rate was the
highest: 91% (95% CI 81–96%) for [18F]FES PET and
80% (95% CI 55–93%) for [18F]FDHT PET. Visual in-
terobserver agreement was not significantly different
between the 10 different patients in this study: P =
0.159 for [18F]FES PET and P = 0.387 for [18F]FDHT
PET.
An important aspect in the identification of tumour
lesions is how well tracer uptake can be distinguished
from background uptake in normal reference tissue.
The TBR of [18F]FDHT was significantly lower than
that of [18F]FES (Fig. 2). In bone lesions, the mean
TBR of [18F]FDHT was 2.0 (± SD 0.6) versus 3.3 (±
SD 2.2) for [18F]FES (P = 0.003). In addition, in
lymph node lesions, the mean [18F]FDHT TBR was
4.6 (± SD 1.9) compared to 10.7 (± SD 8.4) for
[18F]FES (P < 0.0001).
Fig. 1 Tumour lesions detected with conventional imaging, [18F]FES and [18F]FDHT PET
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Quantitative analyses of [18]FES and [18F]FDHT PET
images
Out of 120 lesions, a total of 94 and 95 were quantified
by both observers on [18F]FES and [18F]FDHT PET, re-
spectively. The other lesions were not quantified by one
or both of the observers as a result of overlap with adja-
cent organs with high physiological tracer uptake, unless
there was a clear anatomical substrate on other imaging
modalities allowing for reliable VOI definition.
In general, interobserver agreement was excellent for
PET quantification (Fig. 3) of all lesions combined (i.e.
visible on PET or seen on conventional imaging). The
ICCs for quantification of SUVmax, SUVpeak and SUV-
mean on [
18F]FES PET were 0.98 (95% CI 0.96–0.98), 0.97
(95% CI 0.96–0.98) and 0.89 (95% CI 0.83–0.92). For
[18F]FDHT PET, the ICCs were lower with 0.78 (95% CI
0.66–0.85), 0.76 (95% CI 0.63–0.84) and 0.75 (95% CI
0.62–0.84), respectively.
In addition, [18F]FES (Fig. 4) and [18F]FDHT PET (Fig.
5) quantification was analysed separately with Bland Alt-
man plots for all lesions visible on PET or lesions only
visible on conventional imaging (hence, PET-negative le-
sions). For [18F]FES PET, PET-positive lesions showed
excellent quantitative interobserver agreement with
mean differences < 2% and 95% limits of agreement
(LOA95%) being narrower for SUVmax (LOA95% − 31.3 to
34.3%) and SUVpeak (LOA95% − 31.1 to 28.4%), com-
pared to SUVmean (LOA95% − 46.5 to 44.3%). More dif-
ferences were shown for PET-negative lesions with
mean interobserver differences < 14% and larger
LOA95% (within ± 75%), but note that absolute differ-
ences between observers were generally low due to a low
SUV. Similarly, for [18F]FDHT PET, interobserver agree-
ment was better for PET-positive (mean interobserver
differences < 7%, LOA95% within ± 45 %) compared to
PET-negative lesions (mean interobserver differences <
12%, LOA95% within ± 76%). SUVmax and SUVpeak
showed a better interobserver agreement in comparison
to SUVmean for the quantification of lesions visible on
[18F]FES PET, while on [18F]FDHT PET the different
SUV parameters were comparable.
Higher levels of tracer accumulation in PET positive
lesions were not associated with improved interobserver
agreement (for [18F]FES PET: Spearman r = 0.04, 0.26
and 0.14 for SUVmax, SUVpeak and SUVmean, respectively
and for [18F]FDHT PET: Spearman r = 0.00, r = 0.03
and r = − 0.17, respectively). In addition, there was no
correlation between tumour size and interobserver
agreement (for [18F]FES PET: Spearman r = 0.10, r =
0.08 and r = 0.06, for SUVmax, SUVpeak and SUVmean, re-
spectively and for [18F]FDHT PET: Spearman r = − 0.07,
r = − 0.16 and r = − 0.42, respectively).
The added value of quantitative assessment in
comparison to visual assessment
Based on previous studies, [18F]FES and [18F]FDHT
SUVmax cut-off levels of 1.5 and 1.9, respectively, have
been identified. There are however limited data on
quantitative thresholds and corresponding cut-off values
for SUVpeak and SUVmean. Based on linear regression of
all lesions quantified in this study, an SUVmax cut-off of
1.5 on [18F]FES PET corresponded with an SUVpeak of
1.2 and an SUVmean of 1.1 (Supplementary figure S1),
and for [18F]FDHT PET, an SUVmax cut-off of 1.9 corre-
sponded with an SUVpeak of 1.6 and an SUVmean of 1.3.
Table 2 Visual interobserver agreement for lesions visible (A, C)
and not visible on conventional imaging (B, D) on [18F]FES and
[18F]FDHT PET, respectively
A Visual interobserver agreement on [18F]FES PET for lesions
visible on conventional imaging
Observer 1
Observer 2 Visible Not visible Not evaluablea Total
Visible 24 3 2 29
Not visible 6 22 4 32
Not evaluablea 2 6 0 8
Total 32 31 6 69
B Visual interobserver agreement on [18F]FES PET for lesions not
visible on conventional imaging
Observer 1
Observer 2 Visible Not visible Not evaluablea Total
Visible 26 3 11 40
Not visible 2 1b 3 6
Not evaluablea 4 1 0 5
Total 32 5 14 51
C Visual interobserver agreement on [18F]FDHT PET for lesions
visible on conventional imaging
Observer 1
Observer 2 Visible Not visible Not evaluablea Total
Visible 9 8 1 18
Not visible 11 27 1 39
Not evaluablea 0 11 1 12
Total 20 46 3 69
D Visual interobserver agreement on [18F]FDHT PET for lesions not
visible on conventional imaging
Observer 1
Observer 2 Visible Not visible Not evaluablea Total
Visible 6 2 11 19
Not visible 1 10c 6 17
Not evaluablea 9 4 2 15
Total 16 16 19 51
aNot evaluable lesions due to overlap with adjacent organs with high
physiological tracer uptake
bLesions identified on [18F]FDHT PET
cLesions identified on [18F]FES PET
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For diagnostic purposes, it is important to identify all
receptor positive tumour lesions. Therefore, we com-
pared visual and quantitative tracer uptake above/below
cut-off levels (Table 3). In 3% and 1% of the lesions
scored visually positive on [18F]FES PET by observer 1
and 2 respectively, SUVmax was below the threshold of
1.5. For [18F]FDHT PET, 14% of the visually positive le-
sions scored by observer 1 as well as observer 2 had an
SUVmax below the threshold of 1.9. There were no struc-
tural differences between observer 1 and 2. The discrep-
ancies were mostly seen in lesions located in tissue with
low background uptake such as skin and lung metastases
(Supplementary table S1). Conversely, in 44% and 39%
of the lesions scored visually negative on [18F]FES PET
by observer 1 and 2, respectively, SUVmax was ≥ 1.5.
Similarly, 31% and 52% of the visually negative lesions
had an SUVmax ≥ 1.9 on [
18F]FDHT PET, respectively.
However, in most cases (60%), we observed overlap with
organs having high physiological tracer accumulation
such as the liver and bowel, followed by lesions that
were determined to be visually positive at second glance
(32%). After correction for these effects, ≤ 4% of the
visually negative lesions had a SUVmax above cut-off for
both tracers.
Comparing the impact of the different SUV parame-
ters on discrepancies between visual and quantitative as-
sessments showed no significant differences with the
only exception that SUVmean showed less visually nega-
tive lesions above cut-off on [18FES]PET than SUVmax or
SUVpeak for observer 1 (P = 0.008 and P = 0.001, re-
spectively), but not for observer 2 (P = 0.125 and P =
0.063, respectively).
Discussion
Interobserver variability is an important step in the clin-
ical application of diagnostic tools. Here, we showed that
both visual and quantitative evaluation were highly re-
producible between independent observers evaluating
[18F]FES PET at separate centres using different scanners
and software. Visual positive and negative absolute
agreement was > 80%, with a kappa of 0.67. Also, the in-
terobserver reliability of quantitative metrics was excel-
lent for SUVmax and SUVpeak (ICC of 0.98 and 0.97,
respectively) and good for SUVmean (ICC of 0.89). In
comparison, staging patients with breast cancer showed
similar results for bone scintigraphy (kappa 0.62–0.78)
and [18F]FDG PET (kappa 0.65 and an ICC of 0.93 for
the quantification of [18F]FDG uptake) [22–26].
Fig. 2 The difference in tumour-background ratio between [18F]FES and [18F]FDHT PET shown visually (a) and quantitatively (mean ± SD) for
bone and lymph node lesions (b). The arrows in a show a bone lesion in the right os ilium visible on [18F]FES PET which is only subtly visible on
[18F]FDHT PET. Note, there is physiological tracer uptake of [18F]FES in the liver, gallbladder, intestine, bladder and for [18F]FDHT also in
the bloodpool
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[18F]FDHT PET also showed good interobserver reli-
ability for quantitative assessments with ICCs ≥ 0.75.
These values are slightly lower than those of [18F]FES
PET, and this was probably due to the lower lesional
[18F]FDHT uptake, because quantitative agreement ac-
cording to Bland Altman analyses were comparable for
both tracers. The TBR of [18F]FDHT was considerably
lower compared to [18F]FES. This probably explains the
higher variability in visual interpretation (kappa = 0.23),
mainly caused by a low visual positive agreement (49%)
in lesions already identified by conventional imaging
modalities, while positive agreement in lesions not iden-
tified by conventional imaging was much higher (80%),
as well as negative visual agreement between observers
(74%). An important impeding factor was the signifi-
cantly lower TBR of [18F]FDHT in bone and lymph node
lesions compared to [18F]FES PET. The TBR of
[18F]FDHT in the current study (2.0 for bone and 4.6 for
lymph nodes) was also lower than in prostate cancer
metastases (3.3 for bone and 5.7 for soft tissue metasta-
ses) with an SUVmax three times higher in prostate
cancer (7.1–9.1 versus 2.0 in the present breast cancer
study) [27, 28]. This suggests that higher AR expression
likely results in better interobserver reliability.
Our study had some limitations. There were only a
limited number of patients included in this study. How-
ever, receptor expression between lesions within a single
patient can be heterogeneous [29], which was confirmed
in the present study resulting in the coverage of a large
range of data in 120 lesions [8]. In addition, we showed
there was no within-patient correlation in visual assess-
ments. A second limitation is a substantial number of
‘not evaluable’ lesions, due to overlap with adjacent or-
gans with high physiological background. The decision
for evaluability was left to each observer individually,
which may have contributed to the low agreement (≤
6%) on these ‘not evaluable lesions’. For future studies,
we recommend that all lesions with physiological back-
ground overlap from the liver, gallbladder, intestine,
bladder and for [18F]FDHT also from bloodpool are
regarded as not evaluable. A third limitation is the lack
of robust [18F]FES and [18F]FDHT thresholds for test
Fig. 3 Intraclass correlation coefficients for all quantified tumour lesions on [18F]FES (n = 94) using SUVmax, SUVpeak and SUVmean (a, b and c) and
[18F]FDHT PET (n = 95) (d, e and f). Note: not quantifiable lesions by one or both of the observers were excluded as a result of overlap with
adjacent organs with high physiological tracer uptake
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positivity. We used an SUVmax cut-off of 1.5 for [
18F]FES
and 1.9 for [18F]FDHT PET based on previous data cor-
responding with ER and AR positivity in biopsies and so
far showing the best predictive value for response to
endocrine therapy [8, 9, 30, 31]. Some studies suggested
an SUVmax cut-off of 2.0 for [
18F]FES PET, taking into
account the background [18F]FES uptake in normal tis-
sues which can exceed the cut-off of 1.5 [29–31]. Tissue
specific cut-off values may indeed be more appropriate
as there are responders to endocrine therapy with a
tumour SUVmax < 2.0. In the current study, up to 20% of
the visually positive lesions had an SUVmax < 2.0, while
< 3% had an SUVmax < 1.5 (Supplementary table S2).
For diagnostic purposes, simple visual assessment of
[18F]FES uptake may suffice to determine the receptor
status of a tumour lesion (agreement was high between
visual assessment and the applied SUVmax cut-off value
of 1.5 for ER-positivity). True discrepancies between visi-
bility and corresponding uptake above or below cut-off
were low (< 4%), making quantification of visually nega-
tive lesions not only cumbersome, but also unnecessary.
Also, quantification of lesions without visual [18F]FES
uptake leads to higher interobserver variability due to
differences in VOI definition. However, quantification
remains a helpful tool for nuclear medicine physicians in
‘equivocal [18F]FES lesions’. In addition, quantification is
useful to measure receptor availability over time for the
evaluation of treatment effects. In contrast, quantifica-
tion of [18F]FDHT uptake is still required in future
breast cancer studies, as we have shown relatively low
visual agreement.
The role of [18F]FES and [18F]FDHT PET in addition
to conventional imaging modalities needs to be defined
further. It has to be taken into account that besides par-
tial volume effects and constraints due to background
tracer uptake limiting their detection, receptor expres-
sion can be heterogeneous and variable during the
course of the disease [11, 32]. In addition, treatment
may induce changes in receptor expression, but also
eradicated tumour cells can leave a visible lesion on con-
ventional imaging (e.g. sclerotic bone lesions), in absence
of viable tumour cells. In the current study with heavily
pretreated patients, 42–46% and 26–29% of the lesions
identified by conventional imaging were detected on
[18F]FES and [18F]FDHT PET, respectively. Vice versa,
only approximately 50% of the lesions observed on
Fig. 4 Bland Altman plots showing the % differences in SUVmax, SUVpeak and SUVmean between observers for lesions visible on [
18F]FES PET (a, b,
c) or only visible on conventional imaging (d, e, f). The dashed lines represent the mean difference between observers ± 95% limits of
agreement (LOA95%)
Mammatas et al. EJNMMI Research           (2020) 10:40 Page 9 of 12
Fig. 5 Bland Altman plots showing the % differences in SUVmax, SUVpeak and SUVmean between observers for lesions visible on [
18F]FDHT PET (a,
b, c) or only visible on conventional imaging (d, e, f)
Table 3 Discrepancies between visual and quantitative assessments (above/below cut-off values for receptor positivity) for [18F]FES
(A) and [18F]FDHT PET (B)
A [18F]FES Observer 1 Observer 2
Visible (n = 64) Not visible (n = 36) Visible (n = 69) Not visible (n = 38)
SUVmax ≥ 1.5 62 (97%) 16 (44%) 68 (99%) 15 (39%)
SUVmax < 1.5 2 (3%) 20 (56%) 1 (1%) 23 (61%)
SUVpeak ≥ 1.2 54 (84%) 19 (53%) 67 (97%) 16 (42%)
SUVpeak < 1.2 10 (16%) 17 (47%) 2 (3%) 22 (58%)
SUVmean ≥ 1.1 57 (89%) 8 (22%) 67 (97%) 11 (29%)
SUVmean < 1.1 7 (11%) 28 (78%) 2 (3%) 27 (71%)
B [18F]FDHT Observer 1 Observer 2
Visible (n = 36) Not visible (n = 62) Visible (n = 37) Not visible (n = 56)
SUVmax ≥ 1.9 31 (86%) 19 (31%) 32 (86%) 29 (52%)
SUVmax < 1.9 5 (14%) 43 (69%) 5 (14%) 27 (48%)
SUVpeak ≥ 1.6 30 (83%) 25 (40%) 33 (89%) 30 (54%)
SUVpeak < 1.6 6 (17%) 37 (60%) 4 (11%) 26 (46%)
SUVmean ≥ 1.3 31 (86%) 20 (32%) 33 (89%) 30 (54%)
SUVmean < 1.3 5 (14%) 42 (68%) 4 (11%) 26 (46%)
Not evaluable lesions were excluded as reported in Table 2
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[18F]FES PET and [18F]FDHT PET were identified by
conventional imaging.
Therefore, a potential role for [18F]FES PET may be in
staging of early ER-positive breast cancer as an addition
to existing imaging techniques. Standard staging with
[18F]FDG PET can miss low-intermediate grade ER-
positive lesions due to their low metabolic activity [33].
We are currently investigating [18F]FES PET in staging
patients with low grade, ER-positive locally advanced or
recurrent breast cancer versus [18F]FDG PET
(NCT03726931), and in metastatic breast cancer versus
addition to conventional diagnostics (NCT01957332).
The non-invasive visualisation of receptor status in
metastatic lesions with PET offers a number potential
clinical advantages. For example, in case conventional
diagnostics cannot establish a final diagnosis of sus-
pected metastatic breast cancer lesions (e.g. as a result of
inaccessible biopsy sites or repeated biopsy sampling er-
rors). Also, PET imaging may help to determine the hor-
mone receptor status of different tumour sites within a
patient and guide treatment decisions, for instance, to
decide on the origin of a metastatic lesion in case of
multiple primary tumours or to determine whether re-
ceptor conversion occurred in metastases from a single
primary tumour [11]. If validated, this may help with
multimodality treatment strategies for heterogeneous
tumour sites of breast cancer, such as endocrine therapy
for [18F]FES positive lesions combined with a local mo-
dality such as radiotherapy for concurrent [18F]FES
negative lesions [34].
Conclusion
In conclusion, our findings demonstrate that visual and
quantitative evaluation of [18F]FES PET has a high inter-
observer concordance and support the use in clinical
practice. Although [18F]FDHT PET showed relatively
low visual agreement, presumably a result of the low AR
expression and consequently low TBR in patients with
breast cancer, there was good quantitative agreement be-
tween observers, acceptable for further [18F]FDHT PET
imaging studies in breast cancer.
Abbreviations
ER: Oestrogen receptor; AR: Androgen receptor; [18F]FES: 16α-[18F]fluoro-17β-
oestradiol; [18F]FDHT: 16β-[18F]fluoro-5α-dihydrotestosterone,; VOI: Volume of
interest; SUV: Standardised uptake value; TBR: Tumour-background ratio;
ICC: Intraclass correlation coefficient; LOA95%: 95% limits of agreement
Acknowledgements
We thank the patients who participated in this study and their families. In
addition, we acknowledge the efforts of the clinical and imaging teams at
the university medical centres participating in this study.
Authors’ contributions
CS, MvK, AG, HV, EB, ErdV, EldV, OH, GH and WM were responsible for the
study concept and design. LM, CV, OH and AG carried out the data
acquisition. MY, OH and AG performed the quality control of the data. HdV
supervised the statistical analyses. BvdV performed the pathological analyses.
LM and CV prepared the manuscript. CS, MvK, AG, HV, EB, ErdV, EldV, OH, GH,
WM, MY, HdV and BvdV edited and revised the manuscript. All authors read
and approved of the final manuscript.
Funding
This study was financially supported by the Centre for Translational
Molecular Medicine (CTMM) project as part of the Mammary Carcinoma
Molecular Imaging for Diagnosis and Therapeutics (MAMMOTH) project.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in
accordance with the ethical standards of the Institutional Review Board of
University Medical Center, Groningen, and also approved by the Institutional
Review Board of the Amsterdam UMC, location VUmc University Medical
Center, Amsterdam, the Netherlands (File no. 2014.501-NL41954.042.13) and
with the 1964 Helsinki Declaration and its later amendments or comparable
ethical standards. Informed consent was obtained from all individual




The authors declare that they have no competing interests.
Author details
1Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam
UMC, VUmc University Medical Center Amsterdam, de Boelelaan 1117, 1081,
HV, Amsterdam, The Netherlands. 2Department of Medical Oncology,
University of Groningen, University Medical Center Groningen, Hanzeplein 1,
9713, GZ, Groningen, The Netherlands. 3Department of Epidemiology and
Biostatistics, Amsterdam Public Health Institute, Amsterdam UMC, VUmc
University Medical Center Amsterdam, De Boelelaan 1105, 1081, HV,
Groningen, The Netherlands. 4Department of Nuclear Medicine and
Molecular Imaging, University of Groningen, University Medical Center
Groningen, Hanzeplein 1, 9713, GZ, Groningen, The Netherlands.
5Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam,
Amsterdam UMC, VUmc University Medical Center Amsterdam, De Boelelaan
1117, 1081, HV, Amsterdam, The Netherlands. 6Department of Pathology and
Medical Biology, University of Groningen, University Medical Center
Groningen, DHanzeplein 1, 9713, GZ, Groningen, The Netherlands.
Received: 19 November 2019 Accepted: 3 April 2020
References
1. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L,
Fourquet A, et al. ONCOPOOL - a European database for 16,944 cases of
breast cancer. Eur J Cancer. 2010;46:56–71. https://doi.org/10.1016/j.ejca.
2009.09.009.
2. Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, et al.
Immunohistochemical evaluation of hormone receptor status for predicting
response to endocrine therapy in metastatic breast cancer. Breast Cancer.
2006;13:74–83.
3. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen
receptor expression in breast cancer in relation to molecular phenotype:
results from the Nurses’ Health Study. Mod Pathol. 2011;24:924–31. https://
doi.org/10.1038/modpathol.2011.54.
4. Krop I, Colleoni M, Traina T, Holmes F, Estevez L, et al. Results from a
randomized placebo-controlled phase 2 trial evaluating exemestane ±
enzalutamide in patients with hormone receptor–positive breast cancer.
Abstract GS4-07. San Antonio Breast Cancer Symposium. San Antonio,
Texas; 2017.
5. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial
of bicalutamide in patients with androgen receptor-positive, estrogen
receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505–
12. https://doi.org/10.1158/1078-0432.CCR-12-3327.
Mammatas et al. EJNMMI Research           (2020) 10:40 Page 11 of 12
6. Traina TA, Yardley DA, Schwartzberg LS, O'Shaughnessy J, Cortes J, Awada
A, et al. Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+)
breast cancer: subgroup analysis from a phase 2 study of enzalutamide
(ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast
cancer (TNBC) treated with 0-1 prior lines of therapy. J Clin Oncol. 2017;35:
1089. https://doi.org/10.1200/JCO.2017.35.15_suppl.1089.
7. Youk JH, Kim EK, Kim MJ, Lee JY, Oh KK. Missed breast cancers at US-guided
core needle biopsy: how to reduce them. Radiographics. 2007;27:79–94.
https://doi.org/10.1148/rg.271065029.
8. Venema CM, Mammatas LH, Schroder CP, van Kruchten M, Apollonio G,
Glaudemans A, et al. Androgen and estrogen receptor imaging in
metastatic breast cancer patients as a surrogate for tissue biopsies. J Nucl
Med. 2017;58:1906–12. https://doi.org/10.2967/jnumed.117.193649.
9. van Kruchten M, de Vries EG, Brown M, de Vries EF, Glaudemans AW,
Dierckx RA, et al. PET imaging of oestrogen receptors in patients with
breast cancer. Lancet Oncol. 2013;14:e465–75. https://doi.org/10.1016/
S1470-2045(13)70292-4.
10. Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, et al. Diagnostic accuracy
and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the
assessment of oestrogen receptor status in recurrent or metastatic lesions
in patients with breast cancer: a prospective cohort study. Lancet Oncol.
2019;20:546–55. https://doi.org/10.1016/S1470-2045(18)30936-7.
11. van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schroder CP,
Dierckx RA, et al. PET imaging of estrogen receptors as a diagnostic tool for
breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;
53:182–90. https://doi.org/10.2967/jnumed.111.092734.
12. van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van
Faassen M, Kema IP, et al. Measuring residual estrogen receptor availability
during fulvestrant therapy in patients with metastatic breast cancer. Cancer
Discov. 2015;5:72–81. https://doi.org/10.1158/2159-8290.CD-14-0697.
13. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al.
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a
phase 1-2 study. Lancet. 2010;375:1437–46. https://doi.org/10.1016/S0140-
6736(10)60172-9.
14. Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, et al.
Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG
PET) predict progression-free survival on endocrine therapy in patients with
ER+ breast cancer. Clin Cancer Res. 2017;23:407–15. https://doi.org/10.1158/
1078-0432.CCR-16-0362.
15. Liu A, Dence CS, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled
androgens: radiochemical synthesis and tissue distribution studies on six
fluorine-substituted androgens, potential imaging agents for prostatic
cancer. J Nucl Med. 1992;33:724–34.
16. Römer J, Steinbach J, Kasch H. Studies on the synthesis of 16α-[18F]
fluoroestradiol. Appl Rad Isotop. 1996;47:395–9.
17. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W,
et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version
2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/
s00259-014-2961-x.
18. Jansen BHE, Kramer GM, Cysouw MCF, Yaqub MM, de Keizer B, Lavalaye J, et al.
Healthy tissue uptake of (68)Ga-prostate specific membrane antigen (PSMA),
(18)F-DCFPyL, (18)F-fluoromethylcholine (FCH) and (18)F-dihydrotestosterone
(FDHT). J Nucl Med. 2019. https://doi.org/10.2967/jnumed.118.222505.
19. de Vet HC, Mokkink LB, Terwee CB, Hoekstra OS, Knol DL. Clinicians are right not
to like Cohen’s kappa. BMJ. 2013;346:f2125. https://doi.org/10.1136/bmj.f2125.
20. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in
the assessment of majority agreement among multiple observers.
Biometrics. 1977:363–74.
21. Portney LG, Watkins MP. Foundations of clinical research: applications to
practice: Pearson/Prentice Hall Upper Saddle River, NJ; 2009.
22. Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J,
Umutlu L, et al. Evaluation of 18 F-FDG PET/MRI, 18 F-FDG PET/CT, MRI, and
CT in whole-body staging of recurrent breast cancer. Eur J Radiol. 2016;85:
459–65.
23. van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van
Geldere D, et al. Determinants of diagnostic performance of [F-18]
fluorodeoxyglucose positron emission tomography for axillary staging in
breast cancer. Ann Surg. 2002;236:619.
24. Shackleton M, Yuen K, Little AF, Schlicht S, McLachlan SA. Reliability of X-
rays and bone scans for the assessment of changes in skeletal metastases
from breast cancer. Intern Med J. 2004;34:615–20. https://doi.org/10.1111/j.
1445-5994.2004.00637.x.
25. Gutzeit A, Doert A, Froehlich JM, Eckhardt BP, Meili A, Scherr P, et al.
Comparison of diffusion-weighted whole body MRI and skeletal
scintigraphy for the detection of bone metastases in patients with prostate
or breast carcinoma. Skeletal Radiol. 2010;39:333–43. https://doi.org/10.1007/
s00256-009-0789-4.
26. Jacene HA, Leboulleux S, Baba S, Chatzifotiadis D, Goudarzi B, Teytelbaum
O, et al. Assessment of interobserver reproducibility in quantitative 18F-FDG
PET and CT measurements of tumor response to therapy. J Nucl Med. 2009;
50:1760–9. https://doi.org/10.2967/jnumed.109.063321.
27. Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, et al.
Practical approach for comparative analysis of multilesion molecular
imaging using a semiautomated program for PET/CT. J Nucl Med. 2011;52:
1727–32. https://doi.org/10.2967/jnumed.111.089326.
28. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, et al. Bone
metastases in castration-resistant prostate cancer: associations between
morphologic CT patterns, glycolytic activity, and androgen receptor
expression on PET and overall survival. Radiology. 2014;271:220–9. https://
doi.org/10.1148/radiol.13130625.
29. Nienhuis HH, van Kruchten M, Elias SG, Glaudemans A, de Vries EFJ,
Bongaerts AHH, et al. (18)F-fluoroestradiol tumor uptake is heterogeneous
and influenced by site of metastasis in breast cancer patients. J Nucl Med.
2018;59:1212–8. https://doi.org/10.2967/jnumed.117.198846.
30. Dehdashti F, Mortimer JE, Trinkaus K, Naughton MJ, Ellis M,
Katzenellenbogen JA, et al. PET-based estradiol challenge as a predictive
biomarker of response to endocrine therapy in women with estrogen-
receptor-positive breast cancer. Breast Cancer Res Treat. 2009;113:509–17.
https://doi.org/10.1007/s10549-008-9953-0.
31. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch
MJ. Metabolic flare: indicator of hormone responsiveness in advanced
breast cancer. J Clin Oncol. 2001;19:2797–803. https://doi.org/10.1200/JCO.
2001.19.11.2797.
32. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al.
Prospective study evaluating the impact of tissue confirmation of metastatic
disease in patients with breast cancer. J Clin Oncol. 2012;30:587–92. https://
doi.org/10.1200/JCO.2010.33.5232.
33. Groheux D, Giacchetti S, Moretti JL, Porcher R, Espie M, Lehmann-Che J,
et al. Correlation of high 18F-FDG uptake to clinical, pathological and
biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging.
2011;38:426–35. https://doi.org/10.1007/s00259-010-1640-9.
34. Mammatas LH, Verheul HM, Hendrikse NH, Yaqub M, Lammertsma AA,
Menke-van der Houven van Oordt CW. Molecular imaging of targeted
therapies with positron emission tomography: the visualization of
personalized cancer care. Cell Oncol (Dordr). 2015;38:49–64. https://doi.org/
10.1007/s13402-014-0194-4.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Mammatas et al. EJNMMI Research           (2020) 10:40 Page 12 of 12
